II期CELIA试验2年数据:靶向tau抗体oligonucleotide疗法diranersen延缓认知衰退效应随时间增强
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
II期CELIA试验开放标签扩展数据显示,直向tau的反义寡核苷酸疗法diranersen治疗96周后仍继续减缓早期阿尔茨海默病患者的认知、功能和疾病进展衰退;60mg每半年一次的剂量表现最佳,CDR-SB评分较基线差异从76周的26%增至96周的38%,1.09分的治疗差异超过1分有意义阈值。
— Open-label extension data suggest diranersen's treatment effects may build over time
by Judy George, Deputy Managing Editor, MedPage Today
November 18, 2026 • 3 min read
Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested.
At 2 years, diranersen continued to slow clinical decline across measures of cognition, function, and disease progression, reported Lawren VandeVrede, MD, PhD, of the University of California San Francisco, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston.
A 60-mg dose twice a year showed the largest effects; with that regimen, participants had a 1.09-point treatment difference in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score at 96 weeks, surpassing the 76-week CDR-SB score, VandeVrede observed. CDR-SB scores can range from 0 to 18, and a 1-point change is considered meaningful, he added.
Treatment effects were calculated by comparing 60 participants who received diranersen during CELIA's placebo-controlled phase and stayed on the same dose through 2 years with 115 people who were originally assigned to placebo and then moved into the study's open-label extension.
On the CDR-SB, the treatment effect grew from 26% at week 76 to 38% at week 96, VandeVrede said.
Other measurements of cognition and function also improved from 76 to 96 weeks, he added. "The increasing separation observed between 18 months and 2 years is remarkable," VandeVrede noted.
Safety findings through week 96 were generally consistent with data from the placebo-controlled period. The most frequent adverse events were procedural pain, post-lumbar puncture syndrome, headache, and confusional state. Most confusional state events were mild or moderate, occurred within 7 days of dosing, and resolved within 7 days of onset.
Diranersen targets microtubule-associated protein tau (MAPT) RNA. It is designed to reduce both intracellular and extracellular tau.
CELIA was a phase II dose-ranging study of diranersen in individuals with early Alzheimer's disease. It enrolled 416 participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia who had not previously received anti-amyloid therapy.
The study evaluated three doses of diranersen administered intrathecally over the 18-month placebo-controlled treatment period: 60 mg every 6 months, 115 mg every 6 months, and 115 mg every 3 months.
The primary endpoint was an assessment of dose response for change from baseline on CDR-SB scores at week 76. All diranersen doses tested in CELIA slowed cognitive decline, but because the lowest dosage performed best, the drug missed its primary endpoint of demonstrating a clear dose response. The ongoing open-label extension study is evaluating the long-term safety, tolerability, and durability of diranersen's clinical benefit.
"CELIA gave the field its first evidence from a randomized trial that lowering tau may slow cognitive decline, and today's 2-year data suggest that benefit may build over time," said Laura Nisenbaum, PhD, interim chief science officer of the Alzheimer's Drug Discovery Foundation in New York City, who wasn't involved with the study.
"The lowest dose appeared to perform best, but its safety and clinical benefit will need to be confirmed in a larger phase III trial," she noted. "Importantly, diranersen also lowered tau without affecting amyloid, making it a promising candidate to pair with anti-amyloid therapies as the field works toward combination treatments that address the full pathobiology of Alzheimer's."
New data from the placebo-controlled treatment period presented at CTAD showed that, at 18 months, the twice-yearly 60-mg diranersen group had favorable memory, orientation, and executive function scores compared with participants on other doses. Biomarker analyses showed that diranersen reduced tau PET signals and lowered soluble tau biomarker levels.
来源:MedPage Today · medpagetoday.com